Asia Pacific Digital Genome Market Trends and Analysis by 2027

The Asia Pacific digital genome market is expected to reach US$ 4,118.86 million by 2027 from US$ 2,077.27 million in 2019; it is estimated to grow at a CAGR of 9.1% from 2020 to 2027.

The key factors driving the growth of digital genomeare increasing prevalence of chronic diseases and growing funding for genomics in the region. However, dearth of skilled professional is the major factor hindering the market growth in Asia Pacific.

The digital genome is advanced progress in understanding animal and plant genetic material is being driven through advancements in DNA sequencing technology. It helps in gathering information related to chronic diseases and utilized to get an understanding of genetic disorders. A digital genome facilitates instant access to trait sequences to resolve unending custom queries.

According to the World Health Organization (WHO), cancer is one of the leading causes of morbidity and mortality. The WHO also suggests that 30–50% of deaths caused due to cancer can be prevented by adequate treatment in the early stages. In this scenario, personalized medicine offers the most promising approaches to tackle diseases, which have far eluded effective treatments or cures. Biopharmaceutical researchers also predict a 69% increase in the number of personalized medicines in development over the coming five years.

Also, many of the most intractable health challenges, from heart disease to cancer, have a genetic component. Indeed, cancer is best described as a disease of the genome. With digitization, doctors will be able to make decisions about a patient’s cancer treatment informed by a tumor’s genetic make-up. This new knowledge is also making precision medicine a reality by enabling the development of highly targeted therapies that offer the potential for improved treatment outcomes, especially for patients battling cancer. Increasing the adoption of personalized medicines for disease treatments using the patient’s genetic information is expected to aid in offering targeted treatment. This, in turn, is expected to create lucrative growth opportunities for the Asia Pacific digital genome market in the near future.

Asia Pacific countries are expecting to witness huge challenge due to growing COVID-19. Considering the economic operations and geographic condition, the outbreak of disease has affected the healthcare infrastructure in Asia Pacific low-income countries. The Countries in Asia have started studying the genome of corona virus. Similarly, Indian scientists have started genome sequencing of the strains of the coronavirus This is the part of large sequencing project led by the New Delhi-based National Centre for Disease Control. Thus, such genome sequencing activities is expected to favour the growth of digital genome in Asia Pacific region.

Rest of Asia Pacific Digital Genome Market,Revenue and Forecast to 2027 (US$ Mn)

ASIA PACIFICDIGITAL GENOME MARKET SEGMENTATION

By Product

• Sequencing and Analyzer Instruments
• DNA/RNA Analysis
• Sequencing and Analysis Software
• Sequencing Chips
• Sample Prep Instruments

By Application

• Diagnostics
• Drug Discovery
• Academic Research
• Personalized Medicine
• Agricultural
• Other

By End-User

• Diagnostics and Forensic Labs
• Academic Research Institutes
• Hospitals
• Other

By Country

• China
• Japan
• India
• South Korea
• Australia

Company Profiles

• THERMO FISHER SCIENTIFIC INC
• Illumina, Inc
• F. HOFFMANN-LA ROCHE LTD
• QIAGEN
• bioMerieux SA

Asia Pacific Digital Genome Report Scope